% | $
Quotes you view appear here for quick access.

Muscle Pharm Corp. Message Board

  • investora2z investora2z Apr 7, 2013 2:24 PM Flag

    Results are better

    As per the recently declared results, the company has shown improvement in the gross and the net margins. The gross sales were on expected lines at $77.8 million, a 267% rise as compared to $21.2 million for 2011. The gross margins improved by 55% from 13.8% in 2011 to 21.4% in 2012. On the net basis, the net loss decreased from $23.3 million in 2011 to $18.9 million in 2012 (a decline of 18.9%). The management had earlier indicated its focus on improving cost efficiency and investors were waiting for news on the margins. Most importantly, the CEO is expecting the company to turn net positive in 2013 itself. If one considers the management guidance of sales for next year of around $100 million, even a small percentage of net profit can alter the fundamentals significantly. The company is presently debt free. Further, due to equity financing of $18 million recently, the company has sufficient cash on books to provide for its operations. The equity financing was done at $8.50, and that may become the new base for the stock. The next big trigger for the company could be the expected listing on the stock exchanges. The combined effect of growing sales, increasing margins and more liquidity in the stock could attract big investors. The company has recently launched new products like FitMiss (a product range for active women), and has increased marketing efforts by hiring celebrity sportsmen to endorse their products. The market for supplements is competitive, and new launches are a must for companies to maintain growth. There have been other launches in other segments of the market like Purenergy by ChromaDex corporation (CDXC) which contains its patented ingredient PteroPure pterostilbene. The new launches in the supplements market are ultimately increasing the market size. MSLP is getting positioned to gain from the growing market.

    SortNewest  |  Oldest  |  Most Replied Expand all replies
    • Good analysis and summary.

      I like the stock and it's opportunity here. However, I am a little concerned with the launching of FitMiss. While I think it could be a great product, launching an entirely new product line at this point in operations is VERY expensive, and could negatively affect the company at an in-opportune time... Other than that, I do like everything else...

      Sentiment: Strong Buy

2.05-0.05(-2.38%)Sep 23 3:41 PMEDT